Loading...
 
Back to the list
Mediterr J Rheumatol 2018;29(3):120-6
Article Links
Multiparametric autoantibody profiling of patients with systemic sclerosis in Greece
Christos Liaskos1, Emmanouela Marou1, Theodora Simopoulou1, Athanasios Gkoutzourelas1, Maria Barmakoudi1, George Efthymiou1, Thomas Scheper2, Wolfgang Meyer2, Christina G. Katsiari1, Dimitrios P. Bogdanos1, Lazaros I. Sakkas1
Authors Information

1. Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece,

2. Institute of Immunology affiliated to Euroimmun AG, Lübeck, Germany

Keywords: autoantibodies, autoimmune disease, diagnostics, scleroderma
References
  1. Sakkas L I, Chikanza I C, Platsoucas C D. Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol 2006;2:679-85. [https://doi.org/10.1038/ncprheum0346] [PMID: 17133253]
  2. Kalogerou A, Gelou E, Mountantonakis S, et al. Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005;64:1233-5. [https://doi.org/10.1136/ard.2004.027094] [PMID: 16014686]
  3. Sakkas L I, Xu B, Artlett C M, et al. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002;168:3649-59. [PMID: 11907131]
  4. Sakkas L I, Bogdanos D P. Systemic sclerosis: New evidence re-enforces the role of B cells. Autoimmun Rev 2016;15:155-61. [https://doi.org/10.1016/j.autrev.2015.10.005] [PMID: 26497107]
  5. Fritzler M J, Choi M Y. Editorial: Are Autoantibodies Involved in the Pathogenesis of Systemic Sclerosis? Arthritis Rheumatol 2016;68:2067-70. [https://doi.org/10.1002/art.39727] [PMID: 27111351]
  6. Liaskos C, Marou E, Simopoulou T, et al. Disease-related autoantibody profile in patients with systemic sclerosis. Autoimmunity 2017;50:414-421. [https://doi.org/10.1080/08916934.2017.1357699] [PMID: 28749191]
  7. Sakkas L I, Platsoucas C D. Is systemic sclerosis an antigen-driven T cell disease? Arthritis Rheum 2004;50:1721-33. [https://doi.org/10.1002/art.20315] [PMID: 15188347]
  8. Nihtyanova S I, Denton C P. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010;6:112-6. [https://doi.org/10.1038/nrrheum.2009.238] [PMID: 20125179]
  9. Steen V D. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42. [https://doi.org/10.1016/j.semarthrit.2005.03.005] [PMID: 16084222]
  10. Salazar G A, Assassi S, Wigley F, et al. Antinuclear antibody-negative systemic sclerosis. Semin Arthritis Rheum 2015;44:680-6. [https://doi.org/10.1016/j.semarthrit.2014.11.006] [PMID: 25578738]
  11. Ho K T, Reveille J D. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003;5:80-93. [PMID: 12718748]
  12. Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol 2010;37:42-53. [https://doi.org/10.1111/j.1346-8138.2009.00762.x] [PMID: 20175839]
  13. Arnett FC. Is scleroderma an autoantibody mediated disease? Curr Opin Rheumatol 2006;18:579-81. [https://doi.org/10.1097/01.bor.0000245726.33006.c3] [PMID: 17053501]
  14. Villalta D, Imbastaro T, Di Giovanni S, et al. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev 2012;12:114-20. [https://doi.org/10.1016/j.autrev.2012.07.005] [PMID: 22776784]
  15. Koenig M, Dieude M, Senecal J L. Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev 2008;7:588-93. [https://doi.org/10.1016/j.autrev.2008.06.010] [PMID: 18617021]
  16. Mavropoulos A, Liaskos C, Simopoulou T, et al. IL-10-producing regulatory B cells (B10 cells), IL-17+ T cells and autoantibodies in systemic sclerosis. Clin Immunol 2017;184:26-32. [https://doi.org/10.1016/j.clim.2017.04.013] [PMID: 28502678]
  17. Mavropoulos A, Simopoulou T, Varna A, et al. Breg Cells Are Numerically Decreased and Functionally Impaired in Patients With Systemic Sclerosis. Arthritis Rheumatol 2016;68:494-504.[https://doi.org/10.1002/art.39437] [PMID: 26414243]
  18. Gelber A C, Manno R L, Shah A A, et al. Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature. Medicine (Baltimore) 2013;92:191-205. [https://doi.org/10.1097/MD.0b013e31829be125] [PMID: 23793108]
  19. Steen V, Domsic R T, Lucas M, et al. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum 2012;64:2986-94. [https://doi.org/10.1002/art.34482] [PMID: 22576620]
  20. Rodriguez-Reyna T S, Hinojosa-Azaola A, Martinez-Reyes C, et al. Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients. Autoimmunity 2011;44:576-84. [https://doi.org/10.3109/08916934.2011.592886] [PMID: 21875377]
  21. Nandiwada S L, Peterson L K, Mayes M D, et al. Ethnic Differences in Autoantibody Diversity and Hierarchy: More Clues from a US Cohort of Patients with Systemic Sclerosis. J Rheumatol 2016;43:1816-24. [https://doi.org/10.3899/jrheum.160106] [PMID: 27481902]
  22. Krzyszczak M E, Li Y, Ross S J, et al. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies. Clin Rheumatol 2011;30:1333-9. [https://doi.org/10.1007/s10067-011-1751-0] [PMID: 21523365]
  23. Walker U A, Tyndall A, Czirjak L, et al. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis 2009;68:856-62. [https://doi.org/10.1136/ard.2008.091348] [PMID: 18625615]
  24. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-55. [https://doi.org/10.1136/annrheumdis-2013-204424] [PMID: 24092682]
  25. Wodkowski M, Hudson M, Proudman S, et al. Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. Clin Exp Rheumatol 2015;33:S131-5. [PMID: 26315678]
  26. Berger M, Steen V D. Role of anti-receptor autoantibodies in pathophysiology of scleroderma. Autoimmun Rev 2017;16:1029-35. [https://doi.org/10.1016/j.autrev.2017.07.019] [PMID: 28778706]
  27. Classen J F, Henrohn D, Rorsman F, et al. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 2009;60:1137-44. [https://doi.org/10.1002/art.24381] [PMID: 19333949]
  28. Baroni S S, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76. [https://doi.org/10.1056/NEJMoa052955] [PMID: 16790699]
  29. Andrade L E C, Klotz W, Herold M, et al. International consensus on antinuclear antibody patterns: definition of the AC-29 pattern associated with antibodies to DNA topoisomerase I. Clin Chem Lab Med 2018. [https://doi.org/10.1515/cclm-2018-0188] [PMID: 29813025]
  30. Claessens J, Belmondo T, De Langhe E, et al. Solid phase assays versus automated indirect immunofluorescence for detection of antinuclear antibodies. Autoimmun Rev 2018;17:533-40. [https://doi.org/10.1515/cclm-2018-0188] [PMID: 29813025]
  31. Dharamsi J W, Victor S, Aguwa N, et al. Morphea in adults and children cohort III: nested case-control study--the clinical significance of autoantibodies in morphea. JAMA Dermatol 2013;149:1159-65. [https://doi.org/10.1001/jamadermatol.2013.4207] [PMID: 23925398]
  32. Sanchez-Montalva A, Fernandez-Luque A, Simeon C P, et al. Anti-SSA/Ro52 autoantibodies in scleroderma: results of an observational, cross-sectional study. Clin Exp Rheumatol 2014;32:S-177-82. [PMID: 25372801]
  33. Hudson M, Pope J, Mahler M, et al. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 2012;14:R50. [https://doi.org/10.1186/ar3763] [PMID: 22394602]
  34. Lee A Y S. A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity. Rheumatol Int 2017;37:1323-33. [https://doi.org/10.1007/s00296-017-3718-1] [PMID: 28417151]
  35. Cottrell T R, Wise R A, Wigley F M, et al. The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis. Ann Rheum Dis 2014;73:1060-6. [https://doi.org/10.1136/annrheumdis-2012-202849] [PMID: 23606705]
  36. Graf S W, Hakendorf P, Lester S, et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 2012;15:102-9. [https://doi.org/10.1111/j.1756-185X.2011.01688.x] [PMID: 22324953]
  37. Didier K, Bolko L, Giusti D, et al. Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians? Front Immunol 2018;9:541. [https://doi.org/10.3389/fimmu.2018.00541] [PMID: 29632529]
  38. Igusa T, Hummers L K, Visvanathan K, et al. Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Ann Rheum Dis 2018;77:1179-86. [https://doi.org/10.1136/annrheumdis-2018-212999] [PMID: 29678941]
  39. Hoa S, Hudson M, Troyanov Y, et al. Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations. Medicine (Baltimore) 2016;95:e4713. [https://doi.org/10.1097/MD.0000000000004713] [PMID: 27583908]